Ralf Baron1, Emilio Martin-Mola2, Matthias Müller3, Cecile Dubois4, Dietmar Falke3, Ilona Steigerwald3. 1. Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital, Schleswig-Holstein Campus Kiel, Kiel, Germany. 2. Department of Rheumatology, University Hospital La Paz, Autonomous University of Madrid, Madrid, Spain. 3. Medical Affairs Europe & Australia, Grünenthal GmbH, Aachen, Germany. 4. Global Biometrics in Grünenthal Innovation, Grünenthal GmbH, Aachen, Germany.
Abstract
OBJECTIVE: To evaluate the effectiveness and tolerability of tapentadol PR monotherapy versus tapentadol PR/pregabalin combination therapy for severe, chronic low back pain with a neuropathic component. METHODS:Eligible patients had painDETECT "unclear" or "positive" ratings and average pain intensity ≥ 6 (11-point NRS-3 [average 3-day pain intensity]) at baseline. Patients were titrated to tapentadol PR 300 mg/day over 3 weeks. Patients with ≥ 1-point decrease in pain intensity and average pain intensity ≥ 4 were randomized to tapentadol PR (500 mg/day) or tapentadol PR (300 mg/day)/pregabalin (300 mg/day) during an 8-week comparative period. RESULTS: In the per-protocol population (n = 288), the effectiveness of tapentadol PR was clinically and statistically comparable to tapentadol PR/pregabalin based on the change in pain intensity from randomization to final evaluation (LOCF; LSMD [95% CI], -0.066 [-0.57, 0.43]; P < 0.0001 for noninferiority). Neuropathic pain and quality-of-life measures improved significantly in both groups. Tolerability was good in both groups, in line with prior trials in the high dose range of 500 mg/day for tapentadol PR monotherapy, and favorable compared with historical combination trials of strong opioids and anticonvulsants for combination therapy. The incidence of the composite of dizziness and/or somnolence was significantly lower with tapentadol PR (16.9%) than tapentadol PR/pregabalin (27.0%; P = 0.0302). CONCLUSIONS:Tapentadol PR 500 mg is associated with comparable improvements in pain intensity and quality-of-life measures to tapentadol PR 300 mg/pregabalin 300 mg, with improved central nervous system tolerability, suggesting that tapentadol PR monotherapy may offer a favorable treatment option for severe low back pain with a neuropathic component.
RCT Entities:
OBJECTIVE: To evaluate the effectiveness and tolerability of tapentadol PR monotherapy versus tapentadol PR/pregabalin combination therapy for severe, chronic low back pain with a neuropathic component. METHODS: Eligible patients had painDETECT "unclear" or "positive" ratings and average pain intensity ≥ 6 (11-point NRS-3 [average 3-day pain intensity]) at baseline. Patients were titrated to tapentadol PR 300 mg/day over 3 weeks. Patients with ≥ 1-point decrease in pain intensity and average pain intensity ≥ 4 were randomized to tapentadol PR (500 mg/day) or tapentadol PR (300 mg/day)/pregabalin (300 mg/day) during an 8-week comparative period. RESULTS: In the per-protocol population (n = 288), the effectiveness of tapentadol PR was clinically and statistically comparable to tapentadol PR/pregabalin based on the change in pain intensity from randomization to final evaluation (LOCF; LSMD [95% CI], -0.066 [-0.57, 0.43]; P < 0.0001 for noninferiority). Neuropathic pain and quality-of-life measures improved significantly in both groups. Tolerability was good in both groups, in line with prior trials in the high dose range of 500 mg/day for tapentadol PR monotherapy, and favorable compared with historical combination trials of strong opioids and anticonvulsants for combination therapy. The incidence of the composite of dizziness and/or somnolence was significantly lower with tapentadol PR (16.9%) than tapentadol PR/pregabalin (27.0%; P = 0.0302). CONCLUSIONS:Tapentadol PR 500 mg is associated with comparable improvements in pain intensity and quality-of-life measures to tapentadol PR 300 mg/pregabalin 300 mg, with improved central nervous system tolerability, suggesting that tapentadol PR monotherapy may offer a favorable treatment option for severe low back pain with a neuropathic component.
Authors: Robert R Edwards; Robert H Dworkin; Dennis C Turk; Martin S Angst; Raymond Dionne; Roy Freeman; Per Hansson; Simon Haroutounian; Lars Arendt-Nielsen; Nadine Attal; Ralf Baron; Joanna Brell; Shay Bujanover; Laurie B Burke; Daniel Carr; Amy S Chappell; Penney Cowan; Mila Etropolski; Roger B Fillingim; Jennifer S Gewandter; Nathaniel P Katz; Ernest A Kopecky; John D Markman; George Nomikos; Linda Porter; Bob A Rappaport; Andrew S C Rice; Joseph M Scavone; Joachim Scholz; Lee S Simon; Shannon M Smith; Jeffrey Tobias; Tina Tockarshewsky; Christine Veasley; Mark Versavel; Ajay D Wasan; Warren Wen; David Yarnitsky Journal: Pain Date: 2016-09 Impact factor: 7.926
Authors: John D Markman; Maria E Frazer; Shirley A Rast; Michael P McDermott; Jennifer S Gewandter; Amit K Chowdhry; Kate Czerniecka; Webster H Pilcher; Lee S Simon; Robert H Dworkin Journal: Neurology Date: 2014-12-10 Impact factor: 9.910
Authors: Steven P Cohen; Steven Hanling; Mark C Bicket; Ronald L White; Elias Veizi; Connie Kurihara; Zirong Zhao; Salim Hayek; Kevin B Guthmiller; Scott R Griffith; Vitaly Gordin; Mirinda Anderson White; Yakov Vorobeychik; Paul F Pasquina Journal: BMJ Date: 2015-04-16
Authors: Rainer Freynhagen; Michael Serpell; Birol Emir; Ed Whalen; Bruce Parsons; Andrew Clair; Mark Latymer Journal: Pain Pract Date: 2013-11-27 Impact factor: 3.183